Diseases Misdiagnosed as Lymphoma: Kikuchi-Fujimoto disease

Several diseases are mistaken for lymphoma. Here is one of them.

The primary symptoms of lymphoma—enlarged lymph nodes, fever, night sweats, weight loss—are called non-specific because they can apply to many different potential diseases.

Kikuchi-Fujimoto disease

One of those diseases is a rare disease called Kikuchi-Fujimoto disease. It is considered extremely rare. The symptoms include:

  • Tender, enlarged lymph nodes
  • Fever
  • Night sweats
  • Weight loss
  • Rash
  • Nausea
  • Vomiting
  • Sore throat

The disease was first reported in Japan (thus the name) but it occurs in all racial groups.

It has been theorized that the disease is caused by a virus. The vast majority of physicians have never actually seen a case of Kikuchi-Fujimoto disease, but its symptoms can mimic lymphoma to the degree that it can be mistaken as lymphoma.

Typically, the disease goes away after a few months. Treatments are not standardized; they usually involve steroids, immune globulin, or antibiotics. Relapses are uncommon, occurring in between ten and twenty percent of cases.

Knowing the Difference

Determining the difference between lymphoma and Kikuchi-Fujimoto disease comes down to the expertise of the hematopathologist reviewing the patient's biopsy. This is yet another reason to make sure that one's lymphoma biopsy is reviewed by a qualified blood pathologist.

More Articles

More Articles

Amazon.com is pleased to have the Lymphoma Information Network in the family of Amazon.com associates. We've agreed to ship items...

The question ought to be what are myelodysplastic syndromes (MDS), since this is a group of similar blood and bone marrow diseases that...

Merkel Cell Carcinoma (MCC) is a very rare and aggressive skin cancer that usually develops when a person is in his or her 70s. It is...

Radiation Therapy Topics

...

At some point, the Seattle biotech company Cell Therapeutics Inc (CTI) should earn an entry in the Guinness Book of World Records for utter and...

Site Beginnings

This site was started as Lymphoma Resource Page(s) in 1994. The site was designed to collect lymphoma...

Three papers appearing in the journal Blood and pointing towards a regulator-suppressor pill could offer hope to blood cancer...

The US Food and Drug Administration (FDA) has granted a third so-called Breakthrough Therapy Designation for the investigational oral...

The US Food and Drug Administration today has approved an expanded use of Imbruvica (ibrutinib) in patients with...

The U.S. Food and Drug Administration has announced that it has granted "Breakthrough Therapy Designation" for the investigational agent...

According to a new study published in the Proceedings of the National Academy of Sciences, a team from the University of California, San...

Pharmacyclics has announced that the company has submitted a New Drug Application (NDA) to the US Food and Drug Administration (FDA) for...

New research suggests that frontline radioimmunotherapy...

Gilead Sciences has announced results of the company's Phase II study of its investigational compound idelalisib, an oral inhibitor of...

Sitemap